Article Information
History
- March 22, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Sung-Ting Chuang1,
- Henrietta Papp2,3,
- Anett Kuczmog2,3,
- Rebecca Eells4,
- Jose M. Condor Capcha5,6,
- Lina A. Shehadeh5,6,
- Ferenc Jakab2,3 and
- Peter Buchwald*,1,7
- 1Diabetes Research Institute, University of Miami, Miami, Florida, USA
- 2National Laboratory of Virology, University of Pécs, Pécs, Hungary
- 3Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary
- 4Reaction Biology, Malvern, PA, USA
- 5Division of Cardiology, University of Miami, Miami, Florida, USA
- 6Interdisciplinary Stem Cell Institute, University of Miami, Miami, Florida, USA
- 7Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, Florida, USA
- ↵*Corresponding Author: Phone: 305 243-9657, pbuchwald{at}med.miami.edu, Diabetes Research Institute, Miller School of Medicine, University of Miami, 1450 NW 10 Ave, Miami, FL 33136, USA.
Posted March 22, 2022.
Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19
